Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

FDA Wants New First-Line Trial Data for Erbitux

By Pharmaceutical Processing | March 3, 2009

NEW YORK (AP) — Bristol-Myers Squibb Co. and Eli Lilly and Co. said Monday the Food and Drug Administration delayed a new marketing approval for their cancer drug Erbitux, asking for additional study data. The companies are seeking approval to market Erbitux as a first-line, or primary, treatment for squamous cell carcinoma of the head and neck. But they said the FDA wants a new pharmacokinetic study, or one that evaluates how the body processes the drug. The FDA wants to confirm that clinical studies of Erbitux match the way it is marketed. Erbitux is currently approved as a treatment for locally advanced squamous cell carcinomas of the head and neck in patients who are undergoing radiation therapy, or for patients whose disease has returned or progressed after chemotherapy. It is also approved to treat colorectal cancer. The two companies market Erbitux through a partnership. Eli Lilly gained a stake in the arrangement after buying ImClone Systems Inc. in November. Last month, the companies decided to withdraw an application asking to market Erbitux for advanced non-small cell lung cancer.

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE